Cargando…
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 p...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971430/ https://www.ncbi.nlm.nih.gov/pubmed/35361754 http://dx.doi.org/10.1038/s41467-022-29219-2 |
_version_ | 1784679631284076544 |
---|---|
author | Pavot, Vincent Berry, Catherine Kishko, Michael Anosova, Natalie G. Huang, Dean Tibbitts, Tim Raillard, Alice Gautheron, Sylviane Gutzeit, Cindy Koutsoukos, Marguerite Chicz, Roman M. Lecouturier, Valerie |
author_facet | Pavot, Vincent Berry, Catherine Kishko, Michael Anosova, Natalie G. Huang, Dean Tibbitts, Tim Raillard, Alice Gautheron, Sylviane Gutzeit, Cindy Koutsoukos, Marguerite Chicz, Roman M. Lecouturier, Valerie |
author_sort | Pavot, Vincent |
collection | PubMed |
description | The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits robust neutralizing antibody responses in naïve subjects. Here we show that, in macaques primed with mRNA or protein-based subunit vaccine candidates, one booster dose of CoV2 preS dTM-AS03 (monovalent D614 or B.1.351, or bivalent D614 + B.1.351 formulations), significantly boosts the pre-existing neutralizing antibodies against the parental strain from 177- to 370-fold. Importantly, the booster dose elicits high and persistent cross-neutralizing antibodies covering five former or current SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta and Omicron) and, unexpectedly, SARS-CoV-1. Interestingly, we show that the booster specifically increases the functional antibody responses as compared to the receptor binding domain (RBD)-specific responses. Our findings show that these vaccine candidates, when used as a booster, have the potential to offer cross-protection against a broad spectrum of variants. This has important implications for vaccine control of SARS-CoV-2 variants of concern and informs on the benefit of a booster with the vaccine candidates currently under evaluation in clinical trials. |
format | Online Article Text |
id | pubmed-8971430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-89714302022-04-20 Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates Pavot, Vincent Berry, Catherine Kishko, Michael Anosova, Natalie G. Huang, Dean Tibbitts, Tim Raillard, Alice Gautheron, Sylviane Gutzeit, Cindy Koutsoukos, Marguerite Chicz, Roman M. Lecouturier, Valerie Nat Commun Article The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits robust neutralizing antibody responses in naïve subjects. Here we show that, in macaques primed with mRNA or protein-based subunit vaccine candidates, one booster dose of CoV2 preS dTM-AS03 (monovalent D614 or B.1.351, or bivalent D614 + B.1.351 formulations), significantly boosts the pre-existing neutralizing antibodies against the parental strain from 177- to 370-fold. Importantly, the booster dose elicits high and persistent cross-neutralizing antibodies covering five former or current SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta and Omicron) and, unexpectedly, SARS-CoV-1. Interestingly, we show that the booster specifically increases the functional antibody responses as compared to the receptor binding domain (RBD)-specific responses. Our findings show that these vaccine candidates, when used as a booster, have the potential to offer cross-protection against a broad spectrum of variants. This has important implications for vaccine control of SARS-CoV-2 variants of concern and informs on the benefit of a booster with the vaccine candidates currently under evaluation in clinical trials. Nature Publishing Group UK 2022-03-31 /pmc/articles/PMC8971430/ /pubmed/35361754 http://dx.doi.org/10.1038/s41467-022-29219-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pavot, Vincent Berry, Catherine Kishko, Michael Anosova, Natalie G. Huang, Dean Tibbitts, Tim Raillard, Alice Gautheron, Sylviane Gutzeit, Cindy Koutsoukos, Marguerite Chicz, Roman M. Lecouturier, Valerie Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates |
title | Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates |
title_full | Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates |
title_fullStr | Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates |
title_full_unstemmed | Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates |
title_short | Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates |
title_sort | protein-based sars-cov-2 spike vaccine booster increases cross-neutralization against sars-cov-2 variants of concern in non-human primates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971430/ https://www.ncbi.nlm.nih.gov/pubmed/35361754 http://dx.doi.org/10.1038/s41467-022-29219-2 |
work_keys_str_mv | AT pavotvincent proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT berrycatherine proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT kishkomichael proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT anosovanatalieg proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT huangdean proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT tibbittstim proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT raillardalice proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT gautheronsylviane proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT gutzeitcindy proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT koutsoukosmarguerite proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT chiczromanm proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates AT lecouturiervalerie proteinbasedsarscov2spikevaccineboosterincreasescrossneutralizationagainstsarscov2variantsofconcerninnonhumanprimates |